Regulacje i polityka gospodarcza · 09/11/1998

Licensing Opportunity and/or Cooperative Research and Development Agreement (``CRADA'') Opportunity: Drug and Method for the Therapeutic Treatment of Leukemia, Lymphoma, Hairy Cell Leukemia, Hodgkin's Disease, and Other Hematologic Malignancies

The NIH is seeking Licensees to further develop, evaluate, and commercialize anti-Tac (Fv)-PE38, also known as LMB2, immunotoxin for the therapeutic treatment of refractory Leukemia, Lymphoma, Hairy Cell Leukemia, Hodgkin's disease and other hematologic malignancies. Anti- Tac (Fv)-PE38 (LMB2) is a recombinant immunotoxin composed of a single- chain Fv form of the anti-Tac (anti-CD25) monoclonal antibody, which binds to the subunit of the IL2 receptor (also called P55, Tac, or CD25), fused to PE38, a mutant form of Pseudomonas Exotoxin A. Anti-TAC (Fv)-PE38 (LMB2) is very cytotoxic to normal or malignant cells expressing IL2 receptors and is being developed for the therapy of chronic lymphocytic leukemia, lymphoma, Hodgkin's disease and Hairy Cell Leukemia. The goal is to move the Anti-Tac (FV)-PE38 (LMB2) immunotoxin into Phase II and III clinical trials. The inventions claimed in USPN 4,892,827, entitled: ``Recombinant Pseudomonas Exotoxins: Construction of an Active Immunotoxin with Low Side Effects''; USSN 07/865,722, entitled: ``Recombinant Antibody-Toxin Fusion Protein''; USPN 5,696,237, entitled: ``Recombinant Antibody- Toxin Fusion Protein''; and USSN 08/461,825, entitled: